OKYO Pharma (OKYO) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free OKYO Stock Alerts $1.49 +0.10 (+7.19%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 25, 2024 | americanbankingnews.comOKYO Pharma (NASDAQ:OKYO) Shares Down 11.1% May 17, 2024 | msn.comExperts reveal plans to end 'drug loss,' where medicines approved overseas not used in JapanMay 8, 2024 | finance.yahoo.comOKYO Pharma Announces Participation in May 2024 Investor ConferencesApril 30, 2024 | globenewswire.comOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)April 9, 2024 | proactiveinvestors.comOKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventApril 8, 2024 | globenewswire.comOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024April 2, 2024 | globenewswire.comOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryMarch 31, 2024 | msn.comJapan authorities inspect second Kobayashi Pharma factory after deathsMarch 29, 2024 | msn.comJapan dietary supplement maker probes five deathsMarch 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)March 22, 2024 | msn.comOKYO Pharma gains after positive results from Phase 2 dry eye disease trialMarch 22, 2024 | msn.comRelief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage StudyMarch 22, 2024 | proactiveinvestors.comOKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptomsMarch 22, 2024 | globenewswire.comOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101March 21, 2024 | proactiveinvestors.comOKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye diseaseMarch 21, 2024 | globenewswire.comOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialMarch 20, 2024 | proactiveinvestors.comOKYO Pharma to release Phase 2 dry eye disease trial results on FridayMarch 20, 2024 | globenewswire.comOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventMarch 19, 2024 | finance.yahoo.comOKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo FinanceMarch 19, 2024 | msn.comTokyo stocks open lower as gains locked in, BOJ outcome awaitedFebruary 25, 2024 | msn.comOKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12February 20, 2024 | msn.comTokyo stocks open flat as gains locked in, exporters riseFebruary 9, 2024 | proactiveinvestors.comOKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trialFebruary 9, 2024 | finance.yahoo.comOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainFebruary 2, 2024 | msn.comStock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocksJanuary 31, 2024 | finance.yahoo.comOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardJanuary 18, 2024 | msn.comEagles files lawsuit in patent dispute over cancer therapyJanuary 13, 2024 | thestreet.comOKYO Pharma LimitedJanuary 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for OKYO Pharma Amid OK-101’s Promising Phase 2 Results and Increased Approval ProbabilityJanuary 8, 2024 | finance.yahoo.comOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye DiseaseDecember 29, 2023 | benzinga.comOKYO Pharma Stock (NASDAQ:OKYO) Dividends: History, Yield and DatesDecember 9, 2023 | morningstar.comOKYO Pharma Ltd OKYOOctober 31, 2023 | msn.comOKYO Pharma announces $5.84M cash raise and payables reductionOctober 9, 2023 | finance.yahoo.comOKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)September 15, 2023 | finance.yahoo.comOKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary SharesSeptember 13, 2023 | proactiveinvestors.comOKYO Pharma announces share offeringSeptember 13, 2023 | finance.yahoo.comOKYO Pharma Announces Public Offering of Ordinary SharesSeptember 8, 2023 | proactiveinvestors.comOKYO Pharma completes enrollment in Phase 2 clinical trial to treat dry eye diseaseSeptember 8, 2023 | barrons.comOkyo Pharma Ltd.August 30, 2023 | benzinga.comThinking about buying stock in T2 Biosystems, OKYO Pharma, Mullen Automotive, Digital Media Solutions, or Orbital Infrastructure Group?August 30, 2023 | proactiveinvestors.comOKYO Pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-endAugust 29, 2023 | finance.yahoo.comOKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value RuleAugust 15, 2023 | finance.yahoo.comOKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023August 1, 2023 | investorplace.comWhy Is OKYO Pharma (OKYO) Stock Down 19% Today?July 31, 2023 | msn.comOKYO Pharma rebounds on withdrawal of equity offeringJuly 31, 2023 | finance.yahoo.comOKYO Pharma Limited Announces Withdrawal of Public OfferingJuly 28, 2023 | marketwatch.comOKYO Pharma Shares Rise 19% After Trial Agreement With Tufts Medical CenterJuly 28, 2023 | finance.yahoo.comOKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical CenterJuly 27, 2023 | finance.yahoo.comOKYO Pharma Announces Appointment of William A. Clementi as Chief Operating OfficerJune 6, 2023 | finance.yahoo.comOKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… Click here for the details OKYO Media Mentions By Week OKYO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKYO News Sentiment▼1.190.78▲Average Medical News Sentiment OKYO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKYO Articles This Week▼21▲OKYO Articles Average Week Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VXRT News CRDF News MOLN News SGMO News VIGL News LIFE News OMGA News DBVT News BLUE News ATHA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKYO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.